[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"skin-condition\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:skin-condition":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,51,79,103,136,161,180,205],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100643462","coping-strategies-loneliness-and-resilience-in-patients-with-dermatosis-100643462",false,"NCT07640373","Coping Strategies, Loneliness, and Resilience in Patients With Dermatosis","ESDaP3","Inclusion Criteria:\n\n* Patients with skin conditions (inflammatory, autoimmune, cancerous, or genetic skin disorders)\n* Controls: individuals without skin disease\n* Adult participant\n* Participant enrolled in a Social Security system or equivalent\n* Participant who has given consent to participate in the study\n\nExclusion Criteria:\n\n* Participants who are unable to understand the protocol\n* Participants under legal guardianship (guardianship, conservatorship)\n* Participants subject to a future protection order, family authorization, or court-ordered protection\n* Participants who are unable to complete the questionnaires",true,"ALL","18 Years",{"count":20,"type":21},375,"ESTIMATED","INTERVENTIONAL",[24],"NA","The European Society for Dermatology \\& Psychiatry (ESDaP) studies the connection between the skin and the mind. Two previous studies of this type were conducted in 13 and 15 European countries, respectively. The first study assessed the psychological impact of skin diseases (anxiety, depression, sleep disorders), and the second analyzed feelings of stigma, stress, and body dysmorphic disorder (an abnormal perception of one's body).\n\nIn this study, new psychological variables will be examined: coping strategies, loneliness, and resilience.\n\nA total of 23 centers will participate in the ESDaP3 study, located in 15 European countries (Austria, France, Germany, Hungary, Italy, North Macedonia, the Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Turkey, and the United Kingdom).\n\nThe aim of this study is to examine coping strategies, loneliness, and resilience among patients with a skin condition. Coping strategies refer to the various ways a person uses to manage a difficult or stressful situation. Resilience refers to a person's ability to cope with difficult situations, adapt to changes or challenges, and regain a sense of balance despite obstacles. Other factors will be assessed: sleep, anxiety and depression, and quality of life. A questionnaire will be given to your potential partner to assess the impact of the skin condition on their life at this time.\n\nAt the study's sole French site, Brest University Hospital, 250 patients with a skin condition and 125 people without a skin condition will be enrolled.",[27,28,29,30,31,32,33],"Skin Disease","Skin Disorder","Skin Condition","Inflammatory Skin Conditions","Autoimmune Skin Diseases","Cancerous Skin Conditions","Genetic Skin Conditions",[35,36,37],"Adaptation strategies","loneliness","resilience","NOT_YET_RECRUITING","2026-06-05",{"date":41,"type":42},"2026-06-10","ACTUAL",{"date":44,"type":21},"2026-07",{"date":46,"type":21},"2029-10",{"name":48,"class":49},"University Hospital, Brest","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":50},"100639832","effects-of-oral-collagen-drinks-on-human-skin-100639832","NCT07605871","Effects of Oral Collagen Drinks on Human Skin","Inclusion Criteria:\n\n* Healthy Chinese subjects aged 18 to 60 years, both male and female.\n* Wrinkle Severity: Crow's feet graded 2-4; under-eye fine lines graded 2-5; nasolabial folds graded 1-3.\n* Presence of facial skin laxity and sagging.\n* Ability to undergo skin examinations and pre-treatment in the designated test areas.\n* Ability to understand the trial process, participate voluntarily, and sign a written Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* Pregnant or lactating women, or those planning to become pregnant in the near future.\n* Highly sensitive constitution, history of allergic diseases, or history of allergies to cosmetics.\n* Presence of skin diseases (e.g., psoriasis, eczema, atopic dermatitis, severe acne) or other chronic systemic diseases.\n* Skin conditions in the test area such as birthmarks, hyperpigmentation, inflammation, scars, nevi (moles), or hypertrichosis (excessive hair).\n* Use of anti-inflammatory drugs (e.g., oral or topical corticosteroids) within the past month.\n* Use of cosmetics or other products with similar efficacy within the past 2 weeks.\n* Participation in other human clinical trials for cosmetics within the past month.\n* Any other conditions deemed unsuitable for participation based on clinical assessment.","60 Years",{"count":59,"type":21},99,[24],"The objective of this study is to evaluate the effect of oral collagen drink and MAXI collagen drink on human skin condition improvement.",[29,63],"Collagen Synthesis",[65,66,67],"MAXI Collagen","Hydrolyzed collagen","Oral Collagen","RECRUITING","2026-05-18",{"date":71,"type":42},"2026-05-26",{"date":73,"type":42},"2026-05-12",{"date":75,"type":21},"2026-06-30",{"name":77,"class":78},"TCI Co., Ltd.","INDUSTRY",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":50},"100622099","efficacy-evaluation-study-of-vitamin-c-and-glutathione-liquid-sachet-100622099","NCT07379216","Efficacy Evaluation Study of Vitamin C and Glutathione Liquid Sachet","Inclusion Criteria:\n\n* Healthy male or female adults, aged 18-65 years old;\n* Commitment not to use products having activity comparable with that of the product to be tested during the study period;\n* Free of any dermatological or systemic disorder that would interfere with results.\n\nExclusion Criteria:\n\n* Subject with obvious skin surface damage;\n* Subject who had oral or topical medication which may affect skin condition within 1 month;\n* Individuals with known allergies to cosmetics, medications, or foods (especially those allergic to legumes\u002Fsoy);\n* Pregnant or breastfeeding individuals;\n* Received facial laser therapy, chemical peeling in the past 2 months.\n* Individuals unwilling to allow publication or public disclosure of photographs taken as part of the study results","65 Years",{"count":87,"type":21},30,[24],"The objective of this study is to evaluate the effect of liquid vitamin C and glutathione supplements on human skin condition improvement and anti-oxidation.",[29,91],"Anti-Oxidative Stress",[93,94],"Vitamin C supplement","Glutathione supplement","2026-02-02",{"date":97,"type":42},"2026-02-04",{"date":99,"type":42},"2026-01-24",{"date":101,"type":21},"2026-06-01",{"name":77,"class":78},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":16,"sex":17,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":115,"conditions":116,"keywords":121,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":50},"100575657","associations-between-dietary-intake-and-cardiometabolic-and-gut-microbiota-outcomes-100575657","NCT06775132","Associations Between Dietary Intake and Cardiometabolic and Gut Microbiota Outcomes","Associations Between Dietary Intake and Cardiometabolic and Gut Microbiota Outcomes in Singapore Adults","Inclusion Criteria:\n\n1. Able to give informed consent\n2. Adults 21-80 years old\n3. English-literate\n4. Have venous access sufficient to allow for blood sampling as per the protocol\n5. No drastic change of diet for the past 1 year\n6. If taking medication, has been consistently taking antihypertensive\u002Fcholesterol-lowering\u002Ftype-2 diabetic medication for more than 5 years prior to starting the study.\n\nExclusion Criteria:\n\n1. Taking dietary supplements and fermented foods, which may impact the gut microbiota (e.g. antibiotics, prebiotics, probiotics, yogurt, kimchi) 2 months before starting the 1st study visit only.\n2. Taking dietary supplements or medications, which may impact sleep outcomes (e.g. Nutritional Shakes (e.g. Ensure), tryptophan, 5-hydroxytryptophan or melatonin supplementations) 1 month before starting the study.\n3. Taking dietary supplements which may impact the eye outcomes (e.g. Vitamin A, vitamin A-containing multivitamin) 2 months before starting the study.","21 Years","80 Years",{"count":113,"type":21},240,"OBSERVATIONAL","This cross-sectional study aims to investigate the associations between dietary intake, cardiometabolic health markers, and gut microbiota composition in Singapore adults.",[117,118,29,119,120],"Cardiometabolic Risk Factors","Gut -Microbiota","Cognitive Ability, General","Sleep Quality",[122,123,124,125,126],"Endothelial progenitor cells","Gut microbiota","Cardiovascular diseases risk factors","MoCA","Advanced glycation end products","2025-05-19",{"date":129,"type":42},"2025-05-21",{"date":131,"type":42},"2025-02-03",{"date":133,"type":21},"2025-12-30",{"name":135,"class":49},"National University of Singapore",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":16,"sex":143,"minAge":144,"maxAge":57,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":4},"100584636","a-clinical-study-on-pre-operative-intervention-with-products-during-aesthetic-medicine-100584636","NCT06891924","A Clinical Study on Pre-operative Intervention With Products During Aesthetic Medicine","Clinical Study on Pre-operative Intervention With Products to Mitigate Skin Discomfort During Aesthetic Medicine","Inclusion Criteria:\n\n* health females aged 35-60;\n* subjects with rough dark, loose fine lines;\n* no history of cosmetic allergies;\n* subjects are willing to use the test serum on split-face for 28 days;\n* subjects are willing to suffer the Fotona 4D treatment (Frac3 and Piano modes) on the face;\n* subjects are willing to use the basic skincare products for 28 days, and acceptable for split-face use of the test products or the control product for 14 days;\n* written informed consent and portrait right consent were obtained from all participants before study entry.\n\nExclusion Criteria:\n\n* anyone who is pregnant, nursing an infant, or planning a pregnancy during the study;\n* subjects with known allergies or sensitivities to the ingredients in any of the study products;\n* any symptoms of facial flushing, erythema, papules, desquamation, or edema as evaluated by a physician prior to initial screening or Fotona4D Pro treatment;\n* unhealed skin lesions;\n* participated in any other clinical trial within one month;\n* received facial skin treatments including but not limited to lasers, chemical peels, and dermal fillers within one month;\n* taken\u002Finjected anti-allergy medication in the past one month;\n* participants in other clinical trials at the same time;\n* any subjects that the investigator considers ineligible.","FEMALE","35 Years",{"count":146,"type":21},33,[24],"This clinical trial aims to evaluate whether a 14-day pre-operative application of the test product (containing MLYAAT-1002®, a proprietary anti-aging complex) can mitigate skin discomfort during Fotona 4D laser therapy (Frac3 and Piano modes) by comparing clinical evaluation, skin attributes measurement and subject self-assessment.",[150,29,151],"Skin Aging","Skin Manifestations","2025-03-26",{"date":154,"type":42},"2025-04-01",{"date":156,"type":21},"2025-03-25",{"date":158,"type":21},"2025-06-01",{"name":160,"class":78},"Botanee Group Co., Ltd.",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":167,"maxAge":18,"enrollmentInfo":168,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":176,"leadSponsor":178,"locationsCount":50},"100583439","frequency-of-skin-diseases-in-children-with-inborn-errors-of-immunity-100583439","NCT06876337","Frequency of Skin Diseases in Children with Inborn Errors of Immunity","Inclusion Criteria:\n\n* • Age of patients below 18 years old.\n\n  * Both sexes.\n  * Patients diagnosed with IEI according to the clinical and laboratory criteria outlined by the latest International Union of Immunological Societies (IUIS) classification or equivalent recognized diagnostic guidelines.\n\nExclusion Criteria:\n\n* Patients older than 18 years Patients not fulfilling the criteria for diagnosis of IEI or still not diagnosed yet.","1 Day",{"count":169,"type":21},60,"1. To detect the prevalence of skin diseases in patients with IEI in Assiut university Children hospital.\n2. To describe the pattern of dermatological manifestation among IEI patients present at Assiut University Children hospital.",[29],"2025-03-12",{"date":174,"type":42},"2025-03-14",{"date":154,"type":21},{"date":177,"type":21},"2026-03",{"name":179,"class":49},"Assiut University",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":16,"sex":143,"minAge":187,"maxAge":85,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":190,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":50},"100571979","biometrical-evaluation-of-the-efficacy-of-a-food-supplement-versus-placebo-100571979","NCT06727292","Biometrical Evaluation of the Efficacy of a Food Supplement Versus Placebo","FB_BfW","Inclusion Criteria:\n\n* Phototype: I to IV;\n* Subjects with normal to dry skin;\n* Subjects with healthy skin on the study area;\n* Non-smokers;\n* Has normal nutritional habits (not vegetarian\u002Fvegan);\n* Is not pregnant or lactating;\n* Has a BMI of 18 - 33 kg\u002Fm2;\n* Is willing to refrain from taking dietary supplements (at best not at all, in any case not during the last month before study start);\n* Willing not to use any oral products or any nutritional supplementation aiming at improving skin status during the course of the study;\n* No history of malabsorption diseases, liver diseases, or diseases of the lipid metabolism;\n* Uses no medication, which may interact with the study product\n\nExclusion Criteria:\n\n* For women: pregnant or nursing woman or woman planning to get pregnant during the study;\n* Cutaneous pathology on the study zone (eczema, etc.);\n* Subject with make-up on the day of the visit at the laboratory;\n* Use of topical or systemic treatment during the previous weeks liable to interfere with the assessment of the efficacy of the study product:\n\n  * change in anti-wrinkle, smoothing and\u002For firming topical products within previous week on the studied zones,\n  * non-invasive procedures within previous month on the studied zones,\n  * intake of food supplement acting on skin within the three previous months,\n  * invasive procedures:\n\n    * deep chemical peeling within previous 3 months on the studied zones,\n    * mesotherapy, dermapen, laser within previous 6 months on the studied zones,\n    * botox and\u002For hyaluronic acid injections within previous 12 months on the studied zones;\n* Intake of vitamin substances and diets comprising a change of normal eating habits;\n* Known allergy to one or several investigational product´s ingredients;\n* Participation in a nutritional study within the last 30 days;\n* Surgical or internal diseases e.g. a metabolic or endocrine disease that may affect the outcome of the study (e.g. diabetes, liver diseases, kidney disorders) or having a history of medical or surgical events that may significantly affect the study outcome including any cardiovascular disease, skin disease, hypertension (\\>140\u002F90 mm Hg in three repeated measurements).","45 Years",{"count":189,"type":21},66,[24],"The purpose of this clinical trial is to evaluate whether nutritional supplementation over a 2-month period improves skin physiological parameters. This is a national, single-center, double-blind, randomized pilot study.\n\nThe study will be conducted using a supplement and a placebo, the safety of which has been assured by the sponsor.\n\nParticipants will:\n\n* Take a food supplement or a placebo once daily for 2 months\n* Visit the study center at beginning, after 28 days and after 56 days of supplementation.\n* Keep a diary of their skin status and tolerability\n\nThe secondary objective is to evaluate product characteristics and performance during normal use in healthy subjects.",[150,193,29],"Hair Condition",[195],"improvements of skin physiological parameters","2024-12-06",{"date":198,"type":42},"2024-12-10",{"date":200,"type":42},"2024-10-14",{"date":202,"type":21},"2025-05-30",{"name":204,"class":78},"Finzelberg GmbH & Co. KG",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":22,"phases":214,"briefSummary":215,"conditions":216,"keywords":219,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":50},"100571774","application-of-the-belleai-dermatological-image-reference-system-for-patient-diagnosis-in-an-active-clinical-setting-100571774","NCT06724627","Application of the Belle.AI Dermatological Image Reference System for Patient Diagnosis in an Active Clinical Setting","Application of the Belle.AI Dermatological Image Reference System on Patient Diagnosis Within an Active Clinical Setting","Inclusion Criteria:\n\n* Patient must present to walk-in clinic with a primary dermatological complaint.\n* Patient must have the ability and willingness to provide informed consent and comply with study procedures and visits.\n* Participants must have access to the required technology (e.g., smartphone with internet access) and be capable of using it for the required image capture.\n\nExclusion Criteria:\n\n* Patients who are unable to comply with study procedures due to physical or mental health limitations (as assessed by study coordinator).\n* Pediatric, adolescent, and teen patients who present with dermatological conditions on their genitalia will not be included in the study (in support of patient privacy concerns).",{"count":213,"type":21},263,[24],"The goal of this research study is to test a new, investigational tool that uses artificial intelligence (AI) to help primary care providers assess skin conditions. This tool is an AI-powered dermatology image reference app that works with a smartphone. For clarity, the AI makes no diagnoses; it provides reference images. Primary care providers then use their own medical judgement and training to make the diagnosis.\n\nThe sponsor aims to compare the diagnoses made by primary care providers (such as doctors, nurse practitioners, and physician assistants) with the support of the AI tool compared to a panel of dermatologists, who are setting the gold standard. By doing so, the sponsor can determine the value of the AI tool for primary care providers and understand how it might be used alongside traditional clinical care.\n\nThis AI capability complies with FDA regulatory guidelines and is not considered a medical device, similar to a Google image search, which returns similar looking images for reference purposes. For intervention, they healthcare providers use their own training and clinical judgement to make the diagnosis, and not the AI.",[29,217,218],"Dermatology","Dermatology\u002FSkin - Other",[220,221,222,223,217,224],"AI","Artificial Intelligence","Digital Health","Health Equity","Skin Health","2024-12-05",{"date":227,"type":42},"2024-12-09",{"date":229,"type":42},"2024-09-16",{"date":231,"type":21},"2025-06-30",{"name":233,"class":78},"BelleTorus Corporation"]